Express Pharma

Orchid Pharma receives EIR from US FDA

3

The approval was received on successful inspection closure of its Irungattukottai formulations plant in Tamil Nadu

Orchid Pharma has received Establishment Inspection Report ( EIR) from the US health regulator on the successful inspection closure for its Irungattukottai formulations plant in Tamil Nadu.

The facility was inspected by the US FDA in the month of May 2015, it added.

Establishment Inspection Report (EIR) is given to a establishment after the completion of the inspection by FDA.

Orchid is present in segments such as anti-infectives, anti-inflammatory, central nervous system, cardio vascular, nutraceuticals and oral as well as sterile products.

Comments are closed.